Greg Wolf to Combined Modality Therapy
This is a "connection" page, showing publications Greg Wolf has written about Combined Modality Therapy.
Connection Strength
0.486
-
Yoo GH, Moon J, Leblanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J, Wolf G. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg. 2009 Sep; 135(9):869-74.
Score: 0.077
-
Eisbruch A, Lyden T, Bradford CR, Dawson LA, Haxer MJ, Miller AE, Teknos TN, Chepeha DB, Hogikyan ND, Terrell JE, Wolf GT. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002 May 01; 53(1):23-8.
Score: 0.046
-
Teknos TN, Cox C, Barrios MA, Chepeha DB, Bradford CR, Fisher SG, Wolf GT. Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma. Laryngoscope. 2002 May; 112(5):844-51.
Score: 0.046
-
Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J, Pai SI, Sidransky D, Westra WH, William WN, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM. Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. Head Neck. 2017 12; 39(12):2433-2443.
Score: 0.034
-
Gainor DL, Marchiano E, Bellile E, Spector ME, Taylor JMG, Wolf GT, Hogikyan ND, Prince ME, Bradford CR, Eisbruch A, Worden F, Shuman AG. Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx. Otolaryngol Head Neck Surg. 2017 10; 157(4):625-630.
Score: 0.033
-
Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, Peterson L, Carey TE, Walline H, Moyer J, Spector M, Perim D, Prince M, McLean S, Bradford CR, Taylor JM, Wolf GT. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016 07; 38(7):1074-84.
Score: 0.030
-
Gallagher KK, Sacco AG, Lee JS, Taylor R, Chanowski EJ, Bradford CR, Prince ME, Moyer JS, Wolf GT, Worden FP, Eisbruch A, Chepeha DB. Association Between Multimodality Neck Treatment and Work and Leisure Impairment: A Disease-Specific Measure to Assess Both Impairment and Rehabilitation After Neck Dissection. JAMA Otolaryngol Head Neck Surg. 2015 Oct; 141(10):888-93.
Score: 0.029
-
Vainshtein JM, Spector ME, McHugh JB, Wong KK, Walline HM, Byrd SA, Komarck CM, Ibrahim M, Stenmark MH, Prince ME, Bradford CR, Wolf GT, McLean S, Worden FP, Chepeha DB, Carey T, Eisbruch A. Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. Oral Oncol. 2014 May; 50(5):513-9.
Score: 0.026
-
Demiroz C, Vainshtein JM, Koukourakis GV, Gutfeld O, Prince ME, Bradford CR, Wolf GT, McLean S, Worden FP, Chepeha DB, Schipper MJ, McHugh JB. Head and neck squamous cell carcinoma of unknown primary: neck dissection and radiotherapy or definitive radiotherapy. Head Neck. 2014 Nov; 36(11):1589-1595.
Score: 0.026
-
Dobrosotskaya IY, Bellile E, Spector ME, Kumar B, Feng F, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos T, Chepeha DB, Walline HM, McHugh JB, Cordell KG, Ward PD, Byrd S, Maxwell JH, Urba S, Bradford CR, Carey TE, Worden FP. Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx. Head Neck. 2014 May; 36(5):617-23.
Score: 0.025
-
Strojan P, Haigentz M, Bradford CR, Wolf GT, Hartl DM, Langendijk JA, Rinaldo A, Eisbruch A, Mendenhall WM, Forastiere AA, Takes RP, Ferlito A. Chemoradiotherapy vs. total laryngectomy for primary treatment of advanced laryngeal squamous cell carcinoma. Oral Oncol. 2013 Apr; 49(4):283-6.
Score: 0.024
-
Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS, Prince ME, Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol. 2010 Jun 01; 28(16):2732-8.
Score: 0.020
-
Emerick KS, Tomycz L, Bradford CR, Lyden TH, Chepeha DB, Wolf GT, Teknos TN. Primary versus secondary tracheoesophageal puncture in salvage total laryngectomy following chemoradiation. Otolaryngol Head Neck Surg. 2009 Mar; 140(3):386-90.
Score: 0.019
-
Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Tsien CI, D'Silva NJ, Yang K, Kurnit DM, Mason HL, Miller TH, Wallace NE, Bradford CR, Carey TE. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol. 2008 Jul 01; 26(19):3138-46.
Score: 0.018
-
Lin A, Jabbari S, Worden FP, Bradford CR, Chepeha DB, Teknos TN, Liao JJ, Nyquist GG, Tsien C, Schipper MJ, Urba S, Wolf GT, Eisbruch A. Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2005 Dec 01; 63(5):1413-8.
Score: 0.015
-
Terrell JE, Ronis DL, Fowler KE, Bradford CR, Chepeha DB, Prince ME, Teknos TN, Wolf GT, Duffy SA. Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004 Apr; 130(4):401-8.
Score: 0.013
-
Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, Endicott JW, McClatchey K, Henderson WG. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991 06 13; 324(24):1685-90.
Score: 0.005